Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manon Bouchard

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Canadian Family Physician Medecin De Famille Canadien|November 16, 2017
Deprescribing antihyperglycemic agents in older persons: Evidence-based clinical practice guidelineBarbara Farrell, Cody Black, Wade Thompson, et al.
Canadian Family Physician Medecin De Famille Canadien|November 16, 2017
Barbara Farrell, Cody Black, Wade Thompson, et al.
Journal of the Neurological Sciences|May 21, 2023
A systematic review of the potential consequences of abnormal serum levels of vitamin B6 in people living with Parkinson's diseaseJoseph S Modica, Catherine Déry, Ryan Canissario, et al.
Movement Disorders Clinical Practice|July 30, 2025
Efficacy and Safety of Foslevodopa/Foscarbidopa Monotherapy in Patients with Parkinson's DiseaseJason Aldred, Manon Bouchard, Juan Carlos Martínez-Castrillo, et al.
Advances in Experimental Medicine and Biology|July 30, 2017
The Québec NTBC Study, Fernando Alvarez, Suzanne Atkinson, et al.
Clinical Parkinsonism & Related Disorders|February 29, 2024
Continuous subcutaneous foslevodopa/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson's disease: Considerations for initiation and maintenanceVictor S C Fung, Jason Aldred, Martha P Arroyo, et al.
Neurology and Therapy|August 26, 2023
Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 StudyJason Aldred, Eric Freire-Alvarez, Alexander V Amelin, et al.
Neurology and Therapy|October 10, 2023
Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 StudyJason Aldred, Eric Freire-Alvarez, Alexander V Amelin, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Canadian Family Physician Medecin De Famille Canadien|November 16, 2017
Deprescribing antihyperglycemic agents in older persons: Evidence-based clinical practice guidelineBarbara Farrell, Cody Black, Wade Thompson, et al.
Canadian Family Physician Medecin De Famille Canadien|November 16, 2017
Barbara Farrell, Cody Black, Wade Thompson, et al.
Journal of the Neurological Sciences|May 21, 2023
A systematic review of the potential consequences of abnormal serum levels of vitamin B6 in people living with Parkinson's diseaseJoseph S Modica, Catherine Déry, Ryan Canissario, et al.
Movement Disorders Clinical Practice|July 30, 2025
Efficacy and Safety of Foslevodopa/Foscarbidopa Monotherapy in Patients with Parkinson's DiseaseJason Aldred, Manon Bouchard, Juan Carlos Martínez-Castrillo, et al.
Advances in Experimental Medicine and Biology|July 30, 2017
The Québec NTBC Study, Fernando Alvarez, Suzanne Atkinson, et al.
Clinical Parkinsonism & Related Disorders|February 29, 2024
Continuous subcutaneous foslevodopa/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson's disease: Considerations for initiation and maintenanceVictor S C Fung, Jason Aldred, Martha P Arroyo, et al.
Neurology and Therapy|August 26, 2023
Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 StudyJason Aldred, Eric Freire-Alvarez, Alexander V Amelin, et al.
Neurology and Therapy|October 10, 2023
Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 StudyJason Aldred, Eric Freire-Alvarez, Alexander V Amelin, et al.
Pageof 2